Loading...
In December 2012, the FDA approved raxibacumab, a monoclonal antibody that neutralizes toxins produced by Bacillus anthracis, thus preventing disease progression. Developed by Human Genome Sciences under a U.S. government contract after the 2001 anthrax attacks through the U.S. mail, it was granted fast-track designation, priority review, and orphan product status and has already been added to the U.S. Strategic National Stockpile.
Raxibacumab is indicated for prevention of inhalational anthrax in adult and pediatric patients when alternatives are unavailable or inappropriate and, in combination with antibiotics, for treatment of this condition. For adults, it is administered as a single 40-mg/kg dose infused over 2 hours and 15 minutes. Ped…